FDA Drug Recalls

982 recalls · Class II, newest first

Jan 9, 2018 Class II · Moderate risk

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Terminated cGMP deviation Marksans Pharma Inc. NDC 25000-123-27 D-0240-2018

Jan 9, 2018 Class II · Moderate risk

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Terminated cGMP deviation Marksans Pharma Inc. NDC 25000-122-28 D-0239-2018

Jan 9, 2018 Class II · Moderate risk

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Terminated cGMP deviation Marksans Pharma Inc. NDC 25000-121-29 D-0238-2018

Jan 9, 2018 Class II · Moderate risk

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Terminated cGMP deviation Marksans Pharma Inc. NDC 25000-114-30 D-0237-2018

Jan 9, 2018 Class II · Moderate risk

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Terminated cGMP deviation Marksans Pharma Inc. NDC 25000-136-20 D-0236-2018

Jan 9, 2018 Class II · Moderate risk

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Terminated cGMP deviation Marksans Pharma Inc. NDC 25000-117-30 D-0235-2018

Jan 3, 2018 Class II · Moderate risk

Failed Dissolution Specifications: Low out of specification results for dissolution during annual stability testing.

Terminated Dissolution failure AVKARE Inc. NDC 50268-512-15 D-0222-2018

Recalls by year